5,392 reports of this reaction
2.3% of all INSULIN LISPRO reports
#5 most reported adverse reaction
VISUAL IMPAIRMENT is the #5 most commonly reported adverse reaction for INSULIN LISPRO, manufactured by Eli Lilly and Company. There are 5,392 FDA adverse event reports linking INSULIN LISPRO to VISUAL IMPAIRMENT. This represents approximately 2.3% of all 239,540 adverse event reports for this drug.
Patients taking INSULIN LISPRO who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is a less commonly reported adverse event for INSULIN LISPRO, but still significant enough to appear in the safety profile.
In addition to visual impairment, the following adverse reactions have been reported for INSULIN LISPRO:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 5,392 FDA reports for INSULIN LISPRO. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 2.3% of all adverse event reports for INSULIN LISPRO, making it a notable side effect.
If you experience visual impairment while taking INSULIN LISPRO, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.